With half its patients from Asia and only 13% from North America, the Destiny Breast 11 trial's results may not be fully generalizable to US patients. Differences in metabolism, healthcare systems, and side effect reporting across regions can impact outcomes, a key consideration when interpreting global trial data.

Despite strong efficacy data, the drug DV-Toripalimab scored lower than a competitor (2.5 vs 3.0). Experts attribute this confidence gap to its Phase 3 trial being conducted only in China, which raises generalizability concerns and reflects a lack of hands-on experience for Western physicians.

By enrolling more participants, Chinese clinical trials achieve greater statistical power. This reduces the likelihood of both Type 1 (false positive) and Type 2 (false negative) errors, leading to more reliable data and a lower chance of abandoning a truly effective drug.

The debate over Summit's Ivanecimab lung cancer data from its China-based Harmony 6 trial shows the risk of assuming data is globally applicable. Differences in patient populations, such as smoking history in squamous cell carcinoma, can make clinical results from one region non-translatable to another, posing a major challenge for global drug developers.

As it becomes easier and more efficient to run clinical trials in China, U.S. companies are increasingly outsourcing them. This creates a dependency where China could cut off access to trials or withhold critical new drugs, ceding the entire innovation edge.

The INDEPENDENCE trial's initial results were confounded by external factors in specific regions. In Mainland China, restricted transfusion practices and a blood shortage led to a 40% placebo response rate, significantly higher than the drug's response rate in that region. This demonstrates how logistical and healthcare system realities can be critical confounding variables in global clinical studies.

The FDA is requiring higher US patient enrollment in global trials to address concerns that results from predominantly non-US populations (e.g., Asia) may not be generalizable. This reflects worries about differences in prior standard-of-care treatments and potential pharmacogenomic variations affecting outcomes.

J&J overcame skepticism about Legend's impressive but China-based CAR-T data by conducting deep, on-the-ground due diligence. They reviewed patient records and documentation to confirm the data's integrity, which became the foundation for a highly successful global partnership.

Despite media narratives of US-China tensions, Enviva's CEO reports a smooth operational experience in the US. Scientific-driven bodies like the FDA accepted their Chinese clinical data, and US-based investigators have been eager to collaborate, suggesting that on-the-ground scientific and patient-focused priorities can override political friction.